EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP ‐1 Receptor Agonist Therapy

Adar Lopez, Liat Perl iD, Eyal Cohen-Sela iD, Ophir Borger iD, Yael Issan, Hagar Interator, Erez Azoulay, Hadar Moran-Lev iD, Ronit Lubetzky, Shira Zelber-Sagi iD, Yael Lebenthal iD, Avivit Brener iD

Acta Paediatrica · 2026-08 · 115 (8) · 1726-1736

DOI: 10.1111/apa.70554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, online erschienen am 20.04.2026. Verfasst von Adar Lopez und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Pediatric Endocrinology, Diabetes and Metabolism, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Body Composition, Glucagon-Like Peptide-1 Receptor Agonists, Metabolic Syndrome, Pediatric Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components.

Methods

This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based obesity care between 2020 and 2024. GLP‐1 RA therapy (liraglutide or semaglutide) was prescribed and dosed on an individualised basis. BMI and muscle‐to‐fat ratio (MFR) z ‐scores (by bioimpedance), and MetS components (glucose intolerance, hypertension, and dyslipidemia) were evaluated and compared with patients not receiving GLP‐1 RA at corresponding time points. Multivariable regression analyses adjusted for sex, age, physical activity, and length of follow‐up evaluated contributors for improvement in body composition.

Results

Of 67 eligible adolescents, 41 (61.2%) received GLP‐1 RA therapy. The GLP‐1 RA‐treated group experienced greater improvements in BMI z ‐scores (−0.34 [−0.57, −0.07] vs. −0.07 [−0.17, 0.05], p < 0.001), and MFR z ‐scores (0.41 [0.12, 0.56] vs. 0.13 [0.01, 0.25], p = 0.007) compared to those without GLP‐1 RA therapy. GLP‐1 RA treatment duration was identified as the sole contributor to BMI and MFR z ‐score improvements ( R 2 = 0.515, p < 0.001 and R 2 = 0.231, p = 0.012, respectively). A 0.25‐unit decrease in BMI z ‐score and a 0.25‐unit increase in MFR z ‐score were associated with 2.8‐fold and 1.8‐fold higher odds of MetS component improvement, respectively.

Conclusion

Adolescents with obesity under GLP‐1 RA therapy combined with lifestyle intervention demonstrated improvements in body composition and MetS components.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body CompositionGlucagon-Like Peptide-1 Receptor AgonistsMetabolic SyndromePediatric ObesityLiraglutideGlucagon-Like PeptidesHumansFemaleAdolescentMaleSemaglutideRetrospective StudiesChild

Stichwörter der Autor:innen

GLP‐1 receptor agonists (GLP‐1 RA)adolescent obesitybioimpedance analysis (BIA)body compositionmetabolic syndromemuscle‐to‐fat ratio (MFR)

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideLiraglutideGlucagon-Like Peptides

Autor:innen und Institutionen

  • The Institute of Pediatric Endocrinology, Diabetes and Metabolism, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • The Nutrition and Dietetics Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • The School of Medicine, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Pediatric Gastroenterology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel.

ORCID-Profile: Liat Perl, Eyal Cohen-Sela, Ophir Borger, Hadar Moran-Lev, Shira Zelber-Sagi, Yael Lebenthal, Avivit Brener

Zitieren

APA

Lopez, A., Perl, L., Cohen-Sela, E., Borger, O., Issan, Y., Interator, H., Azoulay, E., Moran-Lev, H., Lubetzky, R., Zelber-Sagi, S., Lebenthal, Y., & Brener, A. (2026). Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP ‐1 Receptor Agonist Therapy. Acta Paediatrica, 115(8), 1726-1736. https://doi.org/10.1111/apa.70554

Vancouver

Lopez A, Perl L, Cohen-Sela E, Borger O, Issan Y, Interator H, et al. Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP ‐1 Receptor Agonist Therapy. Acta Paediatrica. 2026;115(8):1726-1736. doi:10.1111/apa.70554

BibTeX
@article{Lopez2026,
  author = {Lopez, Adar and Perl, Liat and Cohen-Sela, Eyal and Borger, Ophir and Issan, Yael and Interator, Hagar and Azoulay, Erez and Moran-Lev, Hadar and Lubetzky, Ronit and Zelber-Sagi, Shira and Lebenthal, Yael and Brener, Avivit},
  title = {Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP ‐1 Receptor Agonist Therapy},
  journal = {Acta Paediatrica},
  year = {2026},
  volume = {115},
  number = {8},
  pages = {1726--1736},
  doi = {10.1111/apa.70554}
}
Kostenlos starten →